Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors

Background This study evaluated the safety, tolerability, pharmacokinetics, immunogenicity and antitumor activity of single and multiple doses of nivolumab in Japanese patients with malignant solid tumors. Subjects and Methods This was an open-label, dose-escalation study in 17 patients with advance...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Invest New Drugs
Hauptverfasser: Yamamoto, Noboru, Nokihara, Hiroshi, Yamada, Yasuhide, Shibata, Takashi, Tamura, Yosuke, Seki, Yoshitaka, Honda, Kazunori, Tanabe, Yuko, Wakui, Hiroshi, Tamura, Tomohide
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer US 2016
Schlagworte:
Phase I Studies
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5352798/
https://ncbi.nlm.nih.gov/pubmed/27928714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0411-2
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge